Neurological Disease Awareness

Understanding
Parkinson's disease
with clarity,
compassion & guidance

A comprehensive evidence-based resource on Parkinson's disease, its variants, early detection, prevention, and living well with the condition.

10M+

People worldwide estimated to be living with Parkinson's disease

Second

Most common neurodegenerative disease after Alzheimer's

1M+

Estimated people living with Parkinson's in India alone

What is Parkinson's

A Neurological Condition Affecting Millions

Parkinson's disease is a progressive neurodegenerative condition caused by the loss of dopamine-producing neurons in the brain's substantia nigra.

It is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 1–2% of people over 60. The disease is characterised by motor symptoms — tremor, rigidity, and slowness of movement — as well as a wide range of non-motor features that can precede motor signs by a decade.

There is currently no cure, but significant advances have been made in symptom management, neuroprotective research, and quality-of-life interventions.

Understanding the neurological basis of Parkinson's disease

Navigate This Resource

What Would You Like to Know?

Disease Overview

Causes, symptoms, diagnosis, and global epidemiology of Parkinson's disease.

🔬

Variants & Syndromes

MSA-C, MSA-P, PSP, CBD, and DLB — related conditions explained clearly.

Early Detection

Pre-motor warning signs, biomarkers, and diagnostic tests explained.

Prevention

Evidence-based lifestyle strategies to reduce Parkinson's risk.

Treatment

Medications, DBS, therapies, and management strategies for PD.

Exercises

Exercise programmes proven to help people living with Parkinson's.

Quality of Life

Emotional, social, nutritional, and practical wellbeing strategies.

Resources

Trusted organisations, support groups, and helplines worldwide.

Key Facts

Understanding the Scale

Parkinson's is a global health challenge with significant and growing prevalence worldwide.

Rising Prevalence

Global PD prevalence has doubled in the past 25 years, driven by aging populations. An estimated 14.2 million people will live with PD by 2040.

Age of Onset

Average onset is in the early-to-mid 60s. Only 5–10% of cases are "early-onset" (before age 50). Incidence rises sharply after age 60.

Sex Difference

PD is 1.5× more common in men globally. Women often experience different symptom profiles, and face longer diagnostic delays.

Global Burden

PD occurs in every country and population. North America and Europe have the highest reported rates; significant underdiagnosis in low-income regions.

Genetic Factors

Fewer than 10–15% of cases have a clear genetic cause. Variants in LRRK2, SNCA, PINK1, and GBA genes are linked to increased risk.

No Cure Yet

Current treatments manage symptoms but do not halt neurodegeneration. Neuroprotective trials are underway. Gene therapy and alpha-synuclein targeting are promising frontiers.

Definition

What Is Parkinson's Disease?

A chronic, progressive neurological disorder characterised by the loss of dopamine-producing neurons in the substantia nigra region of the brain.

Parkinson's disease (PD) is caused by the gradual degeneration of dopaminergic neurons in the substantia nigra — a region of the midbrain vital for smooth, coordinated movement. Dopamine is the neurotransmitter these cells produce; as their numbers decline, movement control is progressively impaired.

A pathological hallmark is the presence of Lewy bodies — abnormal clumps of misfolded alpha-synuclein protein inside neurons. Their spread through the nervous system is thought to underlie the progression of the disease.

PD is a highly heterogeneous condition — two people with the same diagnosis may have very different symptoms, rates of progression, and treatment responses.

Parkinson's is not just a movement disorder. Non-motor symptoms — depression, cognitive changes, sleep disorders — often precede the motor signs and can be more debilitating.

Neurodegeneration in the substantia nigra drives Parkinson's symptoms

Epidemiology

Global & Indian Burden

Parkinson's disease affects people in every country, with prevalence rising as populations age worldwide.

Region	Estimated Prevalence	Key Notes
Global	~10 million (2024)	Rising rapidly; estimated 14.2 million by 2040
North America	~1.2 million (USA)	Well-documented; high diagnosis rates
Europe	~1.2 million	Aging population driving rapid growth
India	~1 million+	Significant underdiagnosis; specialist shortage
China & East Asia	~2+ million	Largest absolute numbers globally
Sub-Saharan Africa	Very low reported	Significant underdiagnosis due to lack of infrastructure

Causes

Why Does Parkinson's Happen?

The exact cause remains unknown in most cases. Evidence points to a combination of genetic susceptibility, environmental exposures, and cellular dysfunction.

Genetic Factors

Variants in genes including LRRK2, SNCA, PINK1, PARK7, PRKN, and GBA have been linked to PD. Fewer than 10–15% of cases have a clear genetic cause.

Environmental Exposures

Prolonged exposure to pesticides (paraquat, rotenone), herbicides, heavy metals, and solvents such as trichloroethylene (TCE) increases risk significantly.

Age

Age is the single greatest risk factor. Average onset is in the early-to-mid 60s; incidence rises sharply with age. Only 5–10% of cases occur before age 50.

Alpha-Synuclein Dysfunction

Misfolded alpha-synuclein clumps into Lewy bodies inside neurons, disrupting cell function. This process may begin in the gut and spread to the brain over years.

Sex

PD is approximately 1.5× more common in men globally. Oestrogen is thought to have neuroprotective effects. Women often experience diagnostic delays.

Mitochondrial Dysfunction

Abnormalities in mitochondria make dopaminergic neurons more vulnerable to damage. This is a key target for emerging neuroprotective therapies.

Motor Symptoms

Movement Symptoms

Motor symptoms are the most visible signs of PD. They typically start on one side of the body and gradually spread.

Resting Tremor

Rhythmic shaking, typically starting in a hand or fingers. Occurs at rest and lessens during movement. Present in ~75% of PD cases.

Bradykinesia

Slowness of movement. Everyday tasks take longer; steps shorten; facial expression diminishes ("masked face"). Often the most disabling motor symptom.

Muscle Rigidity

Stiffness and resistance to movement in limbs or trunk. Causes pain and a stooped posture. Often mistaken for arthritis in early stages.

Postural Instability

Impaired balance, usually appearing in later stages. A leading cause of falls, injury, and hospitalisation. Particularly dangerous in Parkinson's-plus syndromes.

Micrographia

Handwriting that becomes progressively smaller and more cramped. Often an early and subtle sign noticed before other motor symptoms develop.

Speech Changes

Voice may become soft, monotone, or slurred. Swallowing difficulties can develop as the disease progresses, raising aspiration risk.

Non-Motor Symptoms

Beyond Movement

Non-motor symptoms can be more disabling than motor symptoms and often precede the movement problems by years — yet are frequently under-recognised.

Cognitive Changes

Memory difficulties, slowed thinking, and executive dysfunction are common. In later stages, Parkinson's disease dementia can develop in up to 80% of patients.

Depression & Anxiety

Up to 50% of people with PD experience depression, stemming from both emotional impact and neurochemical changes. Often precedes motor diagnosis.

Sleep Disorders

REM sleep behaviour disorder can precede motor symptoms by a decade. Insomnia, excessive daytime sleepiness, and restless legs are common.

Loss of Smell

Reduced sense of smell (hyposmia) affects up to 90% of people with PD and can precede diagnosis by years. Frequently overlooked in clinical assessment.

Autonomic Dysfunction

Constipation (often years before diagnosis), dizziness on standing, urinary urgency, and excessive sweating from autonomic nervous system involvement.

Pain & Fatigue

Chronic musculoskeletal pain and profound fatigue are very common but frequently under-recognised aspects of PD that significantly impact quality of life.

Atypical Parkinsonism

The Parkinson's Spectrum

Parkinson's disease is the most common form of parkinsonism, but several related conditions share its features while affecting additional brain systems and progressing more rapidly.

Parkinson's-plus syndromes — MSA-C, MSA-P, PSP, CBD, and DLB — frequently go misdiagnosed as classic PD, sometimes for several years. Unlike classic PD, they respond poorly to levodopa and progress more rapidly.

Multiple System Atrophy — Cerebellar (MSA-C)

Synucleinopathy · Atypical Parkinsonism

MSA-C is a rare, progressive neurodegenerative disorder where the "C" stands for cerebellar. More prevalent in Asian populations. Both MSA types are caused by alpha-synuclein accumulation in glial cells (not neurons as in PD), distinguishing them from classic PD.

Key Symptoms

Cerebellar ataxia — unsteady, wide-based gait
Difficulty coordinating movements and balance
Slurred or quivering speech (dysarthria)
Abnormal eye movements (nystagmus)
Difficulty swallowing (dysphagia)
Orthostatic hypotension, urinary dysfunction

Cause & Progression

Alpha-synuclein buildup in oligodendroglial cells
Affects cerebellum, brainstem, and autonomic pathways
~50% wheelchair-dependent within 5–6 years
Median survival: 6–10 years from symptom onset
No disease-modifying treatment; poor levodopa response

Multiple System Atrophy — Parkinsonian (MSA-P)

Synucleinopathy · Atypical Parkinsonism

MSA-P closely resembles classic Parkinson's disease early on but involves broader neurological damage, especially to the autonomic nervous system. Commonly misdiagnosed as PD. Key distinction: autonomic symptoms are earlier and more severe, and levodopa provides little lasting benefit.

Key Symptoms

Parkinsonism: slow shuffling gait, stiffness, bradykinesia
Orthostatic hypotension — dizziness/fainting on standing
Urinary urgency, incontinence, or retention
Erectile dysfunction (often early in men)
Sleep apnoea and loud snoring (respiratory stridor)

Cause & Progression

Same pathology as MSA-C: glial alpha-synuclein inclusions
Affects basal ganglia, brainstem, and autonomic centres
Affects ~4 per 100,000 people; both sexes equally
Average age of onset: ~58 years
Typical survival: 7–9 years from diagnosis

🔬 For every person with MSA, there are approximately 40 people with Parkinson's disease in the population. (APDA)

Progressive Supranuclear Palsy (PSP)

Tauopathy · Atypical Parkinsonism

PSP is caused by abnormal tau protein accumulating in specific brain regions. A hallmark is difficulty voluntarily moving the eyes up and down (vertical gaze palsy). Early falls — typically backwards — are another distinguishing sign.

Key Symptoms

Frequent early falls, often backwards
Vertical gaze palsy — difficulty looking up/down voluntarily
Wide-eyed, startled-looking stare
Severe neck stiffness (retrocollis)
Difficulty swallowing and choking risk
Cognitive impairment, frontal lobe dementia, apathy

Cause & Progression

Tau accumulates in brainstem, basal ganglia, and frontal cortex
Typically begins after age 60
Median survival: ~9.7 years from symptom onset
Most require walking aids within 3 years
Poor response to levodopa

Corticobasal Degeneration (CBD) / Corticobasal Syndrome

Tauopathy · Atypical Parkinsonism

CBD involves tau protein accumulation in the cerebral cortex and basal ganglia, causing a strikingly asymmetric presentation. "Alien limb" syndrome — a limb that moves involuntarily — is a distinctive feature.

Key Symptoms

Apraxia — inability to perform purposeful movements despite normal strength
"Alien limb" syndrome — involuntary limb movement
Markedly asymmetric rigidity and stiffness
Limb myoclonus — sudden jerking movements
Language difficulties (aphasia) and cognitive changes

Cause & Progression

Tau protein in cortex and basal ganglia; asymmetric
Typically affects people aged 50–70
Symptoms progress over an average of 6–8 years
Minimal to no response to levodopa
Definitive diagnosis requires brain autopsy

Dementia with Lewy Bodies (DLB)

Synucleinopathy · Atypical Parkinsonism

DLB is the second most common progressive dementia after Alzheimer's. Key features — vivid visual hallucinations, fluctuating cognition, and REM sleep behaviour disorder — appear early, often before significant motor symptoms.

Key Symptoms

Vivid, recurrent visual hallucinations (often detailed)
Fluctuating cognition — confusion alternating with clarity
REM sleep behaviour disorder (acting out dreams)
Parkinsonism: slowness, stiffness, balance problems
Severe sensitivity to antipsychotic medications

Cause & Progression

Alpha-synuclein (Lewy bodies) spreads throughout brain cortex
Often coexists with Alzheimer's pathology
Average survival: ~5–7 years from diagnosis
Acetylcholinesterase inhibitors may help cognition
Antipsychotics must be avoided — risk of severe neuroleptic sensitivity

Quick Comparison

Condition	Protein	Levodopa Response	Hallmark Feature	Survival
Parkinson's Disease	α-synuclein (neurons)	Good (initially)	Resting tremor, asymmetric	Near-normal
MSA-C	α-synuclein (glia)	Poor	Cerebellar ataxia + autonomic failure	6–10 yrs
MSA-P	α-synuclein (glia)	Poor	Parkinsonism + severe autonomic dysfunction	7–9 yrs
PSP	Tau (4R)	Poor	Vertical gaze palsy, backward falls	~9–10 yrs
CBD / CBS	Tau (4R)	Poor	Alien limb, asymmetric apraxia	6–8 yrs
DLB	α-synuclein (widespread)	Variable	Early hallucinations, cognitive fluctuation	~5–7 yrs

Why It Matters

The Importance of Early Diagnosis

By the time motor symptoms appear, up to 80% of dopamine-producing neurons may already be lost — making early detection the most critical frontier in Parkinson's research.

One of the greatest challenges with Parkinson's disease is that neurodegeneration begins years — sometimes a decade or more — before the characteristic motor symptoms appear. This "pre-motor" or "prodromal" period represents a critical window for future neuroprotective interventions.

Currently, there is no single definitive test for PD. Diagnosis is primarily clinical — based on symptoms, history, physical examination, and neurological testing. However, a growing arsenal of biomarkers, imaging tools, and genetic tests is improving early detection.

"Early detection of Parkinson's disease may one day allow disease-modifying therapy to begin before major neuronal loss has occurred." — PPMI, MJFF

Advanced neuroimaging enables earlier and more accurate diagnosis

Pre-Motor Signs

Early Warning Signs

These symptoms can appear years or even a decade before motor signs emerge.

Loss of Smell (Hyposmia)

Reduced or absent sense of smell affects up to 90% of people with PD and can precede diagnosis by many years. A key pre-motor biomarker.

REM Sleep Behaviour Disorder

Physically acting out vivid dreams during sleep. Present in up to 80% of people who will develop PD — often 10+ years before motor symptoms.

Constipation

Chronic constipation (fewer than one bowel movement per day) is among the earliest autonomic signs. Alpha-synuclein may begin accumulating in gut neurons.

Depression & Anxiety

Neurochemical changes in early PD can trigger depression, anxiety, and mood changes years before motor symptoms are noticed.

Low Blood Pressure on Standing

Orthostatic hypotension (dizziness when standing) from early autonomic dysfunction can be a pre-motor indicator.

Subtle Writing Changes

Early micrographia or changes in fine motor control can be a very subtle, early indicator of dopaminergic dysfunction.

Voice Softening

A gradually softening voice (hypophonia) is an early motor sign that is often missed and attributed to other causes.

Cognitive Slowing

Subtle difficulties with multitasking, word-finding, or executive function can precede a formal PD diagnosis in some individuals.

Diagnostic Tools

How Parkinson's Is Diagnosed

Clinical Examination

The gold standard remains a thorough neurological examination by a movement disorder specialist. The UK Brain Bank criteria guide clinical diagnosis.

Levodopa Response Test

A significant improvement in motor symptoms after levodopa administration strongly supports a diagnosis of idiopathic Parkinson's disease.

DaTscan (SPECT Imaging)

Dopamine transporter imaging can confirm reduced dopamine uptake in the basal ganglia, supporting PD diagnosis and distinguishing from essential tremor.

MRI Brain

Standard MRI is usually normal in PD but can help exclude other causes. Specific MRI patterns (e.g. "hummingbird sign" on MRI) support PSP diagnosis.

Genetic Testing

Panel testing for LRRK2, GBA, SNCA, and other variants is available, particularly relevant for early-onset cases or those with family history.

Emerging: CSF & Blood Biomarkers

Alpha-synuclein seed amplification assays (SAA) in CSF show ~85% sensitivity. Blood biomarkers (neurofilament light chain, GFAP) are under active research.

Skin Biopsy for α-Synuclein

A 2024 study showed skin biopsy for phosphorylated alpha-synuclein had high sensitivity and specificity, offering a minimally invasive diagnostic option.

Sleep Study (Polysomnography)

Formal assessment of REM sleep behaviour disorder. A positive result in the right clinical context strongly supports prodromal Parkinson's or related synucleinopathy.

📌 Diagnosis of Parkinson's-plus syndromes (MSA, PSP, CBD) is significantly more challenging and often delayed by 2–4 years from symptom onset. A movement disorder specialist referral is strongly recommended when atypical features are present.

⚠️ Important: These are population-level risk reduction strategies, not guarantees of prevention. No single strategy can eliminate PD risk. Always discuss your personal risk with a neurologist.

Lifestyle & Exercise

Exercise as Neuroprotection

Physical activity has the strongest evidence of any lifestyle intervention for reducing PD risk and slowing progression.

Strong Evidence

Vigorous Aerobic Exercise

Studies show 3+ hours of vigorous aerobic exercise per week is associated with a 45% reduced risk of PD. Exercise promotes BDNF, protects dopaminergic neurons, and improves mitochondrial function. Walking, cycling, swimming, and dancing all count.

Strong Evidence

Caffeine Consumption

Multiple large cohort studies link regular coffee and caffeine intake (2–3 cups/day) with significantly reduced PD risk, especially in men and non-users of post-menopausal HRT. Mechanisms include adenosine receptor antagonism, which is neuroprotective.

Moderate Evidence

Mediterranean / MIND Diet

Diets rich in vegetables, olive oil, fish, nuts, and whole grains are associated with lower PD risk. The MIND diet (Mediterranean-DASH hybrid) specifically shows neuroprotective benefits. High flavonoid intake from berries and citrus is particularly noted.

Moderate Evidence

Tai Chi & Mind-Body Exercise

Tai Chi has shown particular benefits for balance, gait, and fall prevention in PD, and may have preventive value in high-risk populations. 2–3 sessions per week with sustained long-term practice is recommended.

Moderate Evidence

Omega-3 Fatty Acids

Omega-3s (fatty fish, flaxseed, walnuts) have anti-inflammatory properties and may support neuronal membrane integrity. Some studies find an inverse relationship between omega-3 intake and PD risk.

Emerging Evidence

Gut Microbiome Health

Research supports the gut-brain axis in PD pathogenesis — alpha-synuclein misfolding may begin in the gut before spreading to the brain. A fibre-rich diet supporting microbiome diversity, fermented foods, and probiotics may be beneficial.

Environmental

Environmental Risk Reduction

Strong Evidence

🌾 Avoid Pesticide Exposure

Agricultural pesticides — especially paraquat and rotenone — are among the most consistently replicated environmental risk factors for PD. Farm workers and rural populations face higher risk. Wear full PPE when handling pesticides; wash all produce thoroughly.

Strong Evidence

Head Injury Prevention

Traumatic brain injuries (TBI) — especially repeated impacts — are a recognised risk factor for PD. Athletes in contact sports and military veterans face elevated risk. Wear appropriate helmets; follow head injury protocols after any TBI.

Moderate Evidence

Reduce Industrial Chemical Exposure

Trichloroethylene (TCE) — used in metal degreasing and dry cleaning — has been linked to elevated PD risk. Follow occupational safety guidelines; use appropriate PPE.

Moderate Evidence

Quality Sleep

Chronic sleep disruption may accelerate neurodegeneration. Treating REM sleep behaviour disorder early is especially important. Maintain consistent sleep schedules; address insomnia with CBT where possible.

Moderate Evidence

Cognitive & Social Engagement

Maintaining brain reserve through lifelong learning, social engagement, and mentally stimulating activities may reduce dementia risk and support neurological resilience.

Emerging Evidence

Air Quality

Urban air pollution (fine particulate matter PM2.5) has been associated with increased PD incidence in several large epidemiological studies. Minimise exposure to heavy traffic; use air purifiers indoors.

Pharmacological

Medications for Classic Parkinson's

There is currently no disease-modifying treatment for Parkinson's disease. All approved therapies target symptoms, primarily by restoring or mimicking dopamine function.

Levodopa / Carbidopa

The gold standard of PD treatment. Levodopa converts to dopamine in the brain; carbidopa prevents premature conversion outside the brain.

Most effective motor symptom treatment
Remains active for 30+ years after introduction
Long-term use can cause dyskinesias (involuntary movements)
Available as immediate and extended-release formulations

Dopamine Agonists

Mimic the action of dopamine at dopamine receptors. Often used in early PD or combined with levodopa.

Pramipexole, ropinirole, rotigotine (patch)
Cabergoline (less used due to cardiac valve risk)
Apomorphine (injectable) for severe fluctuations
Risk of impulse control disorders (gambling, hypersexuality)

MAO-B Inhibitors

Reduce breakdown of dopamine in the brain. Used as monotherapy early or as adjuncts to levodopa.

Selegiline, rasagiline, safinamide
Mild symptomatic benefit; possible neuroprotective effects under study
Safinamide also has anti-glutamate properties

COMT Inhibitors

Extend the duration of levodopa effect by blocking its breakdown. Used to reduce "off" periods.

Entacapone, opicapone, tolcapone
Opicapone: once-daily dosing
Tolcapone: effective but requires liver monitoring

Amantadine

An antiviral with anti-parkinsonian and anti-dyskinesia properties. Mechanism includes NMDA receptor antagonism.

Used for mild early PD and for levodopa-induced dyskinesias
Extended-release formulation for dyskinesia management
Also used in gait and balance impairment

Anticholinergics

Older agents used primarily for tremor-dominant PD, but with significant side effects limiting use in older adults.

Trihexyphenidyl, benztropine
Useful in younger PD patients with tremor
Avoid in elderly — cognitive side effects, falls risk

Advanced Therapies

Surgical & Device-Based Treatments

Deep Brain Stimulation (DBS)

High-frequency electrical stimulation of specific brain targets (STN or GPi) via implanted electrodes. Most effective advanced therapy for motor fluctuations and dyskinesias.

Suitable for well-selected PD patients after 4–5 years
Reduces "off" time and dyskinesias significantly
Targets: subthalamic nucleus (STN) or globus pallidus interna (GPi)
Adaptive DBS (closed-loop) systems now in trials

Levodopa-Carbidopa Intestinal Gel (LCIG)

Continuous infusion of levodopa gel directly into the small intestine via a gastrostomy tube, providing stable drug delivery.

Reduces motor fluctuations dramatically
Duodopa/Duopa brand names; requires PEG-J tube insertion
Suitable for advanced PD with severe fluctuations

Focused Ultrasound (FUS)

Non-invasive procedure using focused ultrasound waves to ablate targeted brain tissue (thalamus/STN), primarily for tremor-dominant PD.

Unilateral treatment (one side only)
No incision or implant required
FDA-approved for essential tremor and PD tremor
Bilateral treatment being evaluated in trials

Apomorphine Infusion / Pen

Continuous subcutaneous infusion or rescue pen injections of apomorphine (dopamine agonist) for management of severe "off" periods and dyskinesias.

Apokyn pen for acute rescue
CSAI (continuous subcutaneous apomorphine infusion) pump for advanced PD
Risk of skin nodules at infusion sites

Allied Health

Therapies & Rehabilitation

Physiotherapy

Essential for maintaining mobility, balance, and preventing falls. LSVT BIG (intensive amplitude-based training) shows strong evidence for improving movement in PD.

Speech & Language Therapy

LSVT LOUD is an evidence-based programme improving voice volume and clarity. Also addresses dysphagia (swallowing difficulties).

Occupational Therapy

Maintains independence in daily activities (dressing, eating, cooking). Recommends assistive devices. Addresses cognitive fatigue and workplace adaptations.

Neuropsychology

Cognitive rehabilitation strategies, psychological support for depression/anxiety, and management of PD-related cognitive changes and dementia.

Nutritional Guidance

Protein timing with levodopa, Mediterranean diet guidance, management of constipation and weight maintenance — critical aspects of PD management often overlooked.

Palliative Care

Advance care planning and specialist palliative support are important aspects of care in later-stage PD and Parkinson's-plus syndromes, focusing on comfort and dignity.

📌 All treatment decisions must be made in partnership with a qualified neurologist or movement disorder specialist. This information is for educational purposes only.

Why Exercise Matters

Exercise as Medicine

Exercise is one of the most powerful interventions available for people with Parkinson's disease, with evidence for neuroprotective effects, motor improvement, and significantly enhanced quality of life.

Neuroprotective

High-intensity exercise promotes BDNF (brain-derived neurotrophic factor), supports dopaminergic neuron health, and may slow neurodegeneration.

Balance & Falls

Targeted balance and gait training significantly reduces fall frequency — a major cause of morbidity and hospitalisation in PD.

Mood & Sleep

Regular exercise reduces depression, anxiety, and sleep disturbances — common and debilitating non-motor symptoms of PD.

Cognitive Benefits

Aerobic exercise supports cognitive function and may slow dementia progression in people with PD.

Recommended Exercise Types

Key Exercise Programmes

LSVT BIG

Amplitude-Based Movement Training

Large, exaggerated movements to counteract bradykinesia and rigidity. Strong clinical evidence.

Boxing

Rock Steady Boxing for PD

Non-contact boxing training specifically adapted for Parkinson's patients. Improves strength, coordination, and balance.

Tai Chi

Tai Chi Balance Training

Slow, meditative movements that significantly improve balance and reduce falls in people with Parkinson's disease.

Dance

Dance for PD Programme

Evidence-based dance classes designed specifically for people with Parkinson's. Mark Morris Dance Group programme.

Nordic Walking

Nordic Walking for Parkinson's

Pole-assisted walking improves gait, posture, and cardiovascular fitness. Safe and highly accessible exercise option.

Yoga

Yoga & Stretching for PD

Gentle yoga adapted for Parkinson's — improves flexibility, reduces rigidity, and supports emotional wellbeing.

⚠️ Always consult your neurologist and physiotherapist before beginning any new exercise programme. Exercise programmes should be tailored to your individual level of fitness, balance ability, and cardiovascular health.

Wellbeing Pillars

The Pillars of Quality of Life

Living well with Parkinson's is possible with a comprehensive, person-centred approach that addresses physical, emotional, social, and practical dimensions.

Physical Activity

Regular exercise tailored to individual ability — the single most evidence-backed quality-of-life intervention.

Nutrition

Mediterranean diet, hydration, fibre for constipation, protein timing with levodopa medication.

Emotional Health

Addressing depression, anxiety, and grief around diagnosis with therapy, medication, and peer support.

Social Connection

Support groups, maintaining relationships, and combating isolation — critical for mental and physical health.

Sleep Quality

Managing REM sleep disorders, insomnia, and daytime sleepiness with appropriate interventions.

Cognitive Health

Mental stimulation, brain training, and early management of cognitive changes and dementia risk.

Medication Adherence

Consistent medication timing, managing fluctuations, and maintaining open communication with your neurologist.

Carer Support

Carers need their own support, respite, and resources. Caregiver burnout is a serious concern.

Nutrition

Dietary Guidance

Mediterranean Diet

Rich in vegetables, fruits, olive oil, legumes, whole grains, fish. Reduces neuroinflammation and supports brain health.

Protein Timing with Levodopa

Protein competes with levodopa absorption. Many people benefit from taking levodopa 30–45 minutes before protein-rich meals. Discuss timing with your neurologist.

Hydration

Adequate hydration helps manage constipation, orthostatic hypotension, and urinary issues common in PD. Aim for 1.5–2 litres of water daily.

Fibre for Constipation

High-fibre diet (fruits, vegetables, whole grains, psyllium husk) and adequate hydration are first-line approaches for PD-related constipation.

Coffee & Tea

2–3 cups of caffeinated coffee or tea per day may have neuroprotective benefits and can help manage daytime sleepiness.

Curcumin & Polyphenols

Anti-inflammatory plant compounds in turmeric, berries, and dark chocolate may support neuronal health. Include naturally in diet where possible.

International

International Organisations

Parkinson's Foundation

Helpline, research, care guides, and international resources. Leading global PD organisation.

parkinson.org

Michael J. Fox Foundation

World's largest private funder of PD research. Clinical trials, news, and patient resources.

michaeljfox.org

NIH / NINDS

US National Institute of Neurological Disorders and Stroke. Clinical trials, research updates, and patient information.

ninds.nih.gov

CurePSP

Dedicated to PSP, CBD, MSA, and related disorders. Support, research funding, and caregiver resources.

curepsp.org

MSA Coalition

Dedicated support, information, and research funding for Multiple System Atrophy patients and families.

multiplesystematrophy.org

Parkinson's Europe

Pan-European patient advocacy and awareness organisation. Country-specific resources across Europe.

parkinsonseurope.org

LSVT Global

Home of LSVT BIG & LSVT LOUD — the leading evidence-based exercise and speech therapy programmes for PD.

lsvtglobal.com

Dance for PD (Mark Morris)

International programme of adapted dance classes for people with Parkinson's disease.

danceforpd.org

India

Indian Resources

PDMDS — Parkinson's Disease & Movement Disorder Society

Leading Indian PD organisation. Support groups, rehabilitation, caregiver training, and specialist network.

parkinsonssocietyindia.com

Brain Society of India

Neurological awareness and support for Indian patients. Specialist referrals and educational resources.

brainsociety.in

NIMHANS, Bangalore

National Institute of Mental Health and Neurosciences. Premier neurological care and research in India.

nimhans.ac.in

AIIMS New Delhi — Neurology

All India Institute of Medical Sciences. Premier PD research and specialist movement disorder clinic.

aiims.edu

Bibliography

Primary Sources

1.Dorsey ER et al. The Parkinson pandemic. JAMA Neurology, 2018.
2.Parkinson's Foundation. Understanding Parkinson's. parkinson.org
3.NIH/NINDS. Parkinson's Disease Information Page. ninds.nih.gov
4.Michael J. Fox Foundation. PPMI Research. michaeljfox.org
5.Bloem BR et al. Parkinson's disease. Lancet 2021;397:2284–2303.
6.GBD 2021 Study. Global burden of Parkinson's disease. Frontiers in Aging Neuroscience, 2024.
7.WHO. Parkinson Disease: A Public Health Approach. Geneva, 2022.
8.Cleveland Clinic. Parkinson's Disease & Related Disorders. clevelandclinic.org
9.Xu, Ma & Yang. Exercise and mitochondria in PD. Frontiers in Aging Neuroscience, 2025.
10.Bloem BR et al. Exercise updates in Parkinson's. PMC/NLM, 2024.
11.StatPearls / NCBI. Parkinson-Plus Syndrome. ncbi.nlm.nih.gov
12.Parkinson's Europe. Types of Parkinson's. March 2024.
13.Nature npj Parkinson's Disease. Early detection via blood and urine biomarkers. February 2025.
14.Lancet. The epidemiology of Parkinson's disease. 2024;403:293–304.
15.Pereira GM et al. Prevalence of PD in low-to-middle-income countries. npj Parkinson's Disease, 2024.
16.Kishore A et al. Clinical profiles of PD in India. Movement Disorders, 2025.
17.PDMDS. Parkinson's Disease & Movement Disorder Society India. parkinsonssocietyindia.com
18.Stanford Medicine. Parkinson's Exercise Videos. February 2026.
19.Brain Support Network. Four Atypical Parkinsonism Disorders. brainsupportnetwork.org
20.Journal of Neurology (Springer). MSA: emerging biomarkers and clinical trials. March 2024.

⚕ Medical & Legal Disclaimer

Educational Purposes Only: The information on this website is intended solely for general informational and educational awareness purposes. It does not constitute medical advice, diagnosis, or treatment.

Not a Substitute for Medical Care: Always seek the advice of your physician, neurologist, or other qualified health provider regarding any medical condition. Never disregard professional medical advice because of something you have read here.

Treatment Decisions: Treatment for Parkinson's disease is highly individualised and must be determined by qualified healthcare professionals who can evaluate the specific circumstances of each patient.

Emergency Situations: If you or someone else is experiencing a medical emergency, call emergency services immediately (112 in India; 911 in the USA). Do not rely on information from this website in an emergency.

Medical Information Currency: Medical knowledge evolves rapidly. While we have endeavoured to provide accurate, up-to-date information based on sources current as of 2024–2026, always verify medical information with a qualified healthcare professional.

A Note of Thanks & Dedication

Divyansh with his grandmother, Mrs Rita Kapoor

This website is first and foremost dedicated to my grandmother, Mrs Rita Kapoor, who was unexpectedly diagnosed with MSA-C (Multiple System Atrophy — Cerebellar type) in 2025. Her diagnosis was the spark that ignited this project — a desire to understand, to share, and to make sure that no family has to navigate this condition without clear and compassionate information.

It is also dedicated to everyone living with Parkinson's disease and its variants, those who care for them, and the researchers who work every day toward better treatments and, one day, a cure. Your resilience and courage are the reason resources like this exist. Thank you to every organisation, scientist, and clinician whose publicly shared knowledge made this possible — and to Holmdel High School for fostering the spirit of inquiry and purpose that inspired this project.

— Divyansh Kapoor, Holmdel High School, Class of 2028

Created By

Founder & Key Contributor

Divyansh Kapoor

Founder & Key Contributor

Holmdel High School

Class of 2028

Holmdel, New Jersey

This resource was conceived, researched, and built by Divyansh Kapoor as a public awareness initiative to make accurate, compassionate information about Parkinson's disease and related disorders freely accessible to patients, caregivers, students, and the general public. Every section was personally researched and synthesised from peer-reviewed medical literature and leading neurological organisations.

Mission

Why This Was Built

Parkinson's disease affects over 10 million people worldwide, yet accessible, high-quality information remains scarce for many patients and families — particularly in India. This website was built to bridge that gap: to bring together credible science, clinical guidance, and human-centred compassion in one freely available resource.

With Deep Gratitude

Organisations & Institutions Thanked

This resource draws on the work of world-leading organisations dedicated to Parkinson's disease research, care, and advocacy. We are profoundly grateful for their publicly available educational materials.

Parkinson's Foundation

parkinson.org

For their comprehensive educational library, helpline resources, and tireless global advocacy for people living with PD.

Michael J. Fox Foundation

michaeljfox.org

For pioneering the Parkinson's Progression Markers Initiative (PPMI) and funding the world's most ambitious PD biomarker and drug discovery research.

NIH / NINDS

ninds.nih.gov

The US National Institute of Neurological Disorders and Stroke, whose publicly accessible clinical information and research funding underpin much of what we know about PD.

World Health Organization

who.int

For the landmark 2022 Parkinson Disease: A Public Health Approach technical brief, which shaped this resource's global epidemiology sections.

PDMDS — Parkinson's Disease & Movement Disorder Society India

parkinsonssocietyindia.com

For their exceptional work supporting PD patients and families across India and for being the primary source of India-specific clinical and epidemiological data on this site.

CurePSP

curepsp.org

For their compassionate patient resources and research investment into PSP, CBD, MSA, and related atypical parkinsonian disorders — conditions often left in the shadows.

MSA Coalition

multiplesystematrophy.org

For their dedication to raising awareness and funding research for one of the most difficult-to-diagnose and rapidly progressive of the parkinsonian syndromes.

Cleveland Clinic & Stanford Medicine

clevelandclinic.org · med.stanford.edu

For their publicly available movement disorder clinical resources, exercise video libraries, and patient education materials referenced throughout this site.

Parkinson's Europe & Brain Support Network

parkinsonseurope.org · brainsupportnetwork.org

For their accessible, patient-centred guides on atypical parkinsonism and for advocating for those navigating the most complex diagnoses in the Parkinson's spectrum.

Academic Recognition

Researchers & Clinicians Acknowledged

The content of this site rests on the shoulders of the researchers, neurologists, and scientists whose published work has defined our understanding of Parkinson's disease.

Dr. Bas Bloem

Radboud University Medical Centre

Landmark Lancet review on Parkinson's disease (2021) and seminal work on exercise as neuroprotection.

Dr. Ray Dorsey

University of Rochester

Seminal work on the Parkinson's pandemic, environmental risk factors, and telemedicine for neurological care.

Dr. Asha Kishore & PDMDS India Team

Sree Chitra Tirunal Institute, India

Nation-wide multicentre study of PD demographics and clinical profiles in India (Movement Disorders, 2025).

Pereira GM et al.

npj Parkinson's Disease, 2024

Systematic review and meta-analysis of PD prevalence in lower-to-middle-income countries, central to India-specific data used here.

GBD 2021 Collaborators

Frontiers in Aging Neuroscience, 2024

Global, regional, and national epidemiology and trends of Parkinson's disease 1990–2021 — the definitive source for global burden statistics.

Xu, Ma & Yang

Frontiers in Aging Neuroscience, 2025

Intervention strategies for Parkinson's disease — the role of exercise and mitochondria — foundational to the exercises section.

UnderstandingParkinson's diseasewith clarity,compassion & guidance

A Neurological Condition Affecting Millions

What Would You Like to Know?

Disease Overview

Variants & Syndromes

Early Detection

Prevention

Treatment

Exercises

Quality of Life

Resources

Understanding the Scale

Rising Prevalence

Age of Onset

Sex Difference

Global Burden

Genetic Factors

No Cure Yet

Parkinson's Disease Overview

What Is Parkinson's Disease?

Global & Indian Burden

Why Does Parkinson's Happen?

Genetic Factors

Environmental Exposures

Age

Alpha-Synuclein Dysfunction

Sex

Mitochondrial Dysfunction

Movement Symptoms

Resting Tremor

Bradykinesia

Muscle Rigidity

Postural Instability

Micrographia

Speech Changes

Beyond Movement

Cognitive Changes

Depression & Anxiety

Sleep Disorders

Loss of Smell

Autonomic Dysfunction

Pain & Fatigue

Parkinson's-Plus Syndromes & Variants

The Parkinson's Spectrum

Multiple System Atrophy — Cerebellar (MSA-C)

Key Symptoms

Cause & Progression

Multiple System Atrophy — Parkinsonian (MSA-P)

Key Symptoms

Cause & Progression

Progressive Supranuclear Palsy (PSP)

Key Symptoms

Cause & Progression

Corticobasal Degeneration (CBD) / Corticobasal Syndrome

Key Symptoms

Cause & Progression

Dementia with Lewy Bodies (DLB)

Key Symptoms

Cause & Progression

Quick Comparison

Early Detection & Diagnosis

The Importance of Early Diagnosis

Early Warning Signs

Loss of Smell (Hyposmia)

REM Sleep Behaviour Disorder

Constipation

Depression & Anxiety

Low Blood Pressure on Standing

Subtle Writing Changes

Voice Softening

Cognitive Slowing

How Parkinson's Is Diagnosed

Clinical Examination

Levodopa Response Test

DaTscan (SPECT Imaging)

MRI Brain

Genetic Testing

Emerging: CSF & Blood Biomarkers

Skin Biopsy for α-Synuclein

Sleep Study (Polysomnography)

Understanding
Parkinson's disease
with clarity,
compassion & guidance